Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA).

Article Details

Citation
Copy to clipboard

Nordt TK, Moser M, Kohler B, Kubler W, Bode C

Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA).

Thromb Haemost. 1999 Sep;82 Suppl 1:121-3.

PubMed ID
10695501 [ View in PubMed
]
Abstract

In acute myocardial infarction rapid, complete, and sustained reperfusion of the infarct-related coronary artery is the most important therapeutic principle. Lanoteplase or n-PA, a third-generation plasminogen activator consisting of a deletion and point mutant of tissue-type plasminogen activator (t-PA), is a promising agent to approach this therapeutic goal. The molecule exhibits an increased plasma half-life allowing single-bolus administration. In this article, after characterizing the n-PA molecule, the currently available pharmacokinetic and pharmacodynamic data including the results of the InTIME study are reviewed.

DrugBank Data that Cites this Article

Drugs